Dana-Farber Research News 10.15.2026

• by

• October 15, 2026

Dana-Farber Breaks Ground on Lavine Bekenstein Cancer Hospital

Historic ceremony marks the beginning of a new era in cancer care, led by Dana-Farber in collaboration with Beth Israel Deaconess Medical Center

• by

• October 19, 2026

• 4 min

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

• by Meletios Athanasios Dimopoulos, Vania Hungria, Haitao Meng, Atanas Radinoff, Jian Li, Sosana Delimpasi, Ting Niu, Gabor Mikala, Tamas Masszi, Marcelo Capra, Michael Low, Angelo Maiolino, Yan Xu, Xavier Leleu, Vasiliki Pappa, Dominik Chraniuk, Tatiana Konstantinova, Iurii Osipov, Shawn Hakim, Chris Brawley, Gabriela Tubel, Astrid McKeown, Julia Boyle, Sumita Roy-Ghanta, Katja Weisel

• October 17, 2026

Diagnostic performance and pathologic associations of the UroVysion assay in patients with upper tract lesions and negative urinary cytology: a large-scale real-world study of 1,256 patients

• by Longtao Zheng, Bao Guan, Zheng Wu, Yi Ding, Bei Zhang, Xuesong Li, Yanqing Gong

• October 18, 2026